Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Validity of Immunohistochemistry Method in Predicting Her-2 Gene Status and Association of Clinicopathological Variables With It in Invasive Breast Cancer Patients Publisher Pubmed



Gheybi MK1 ; Baradaran A2 ; Mohajeri MR3 ; Ostovar A4 ; Hajalikhani P5 ; Farrokhi S6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Persian Gulf Tropical Medicine Research Centre, Bushehr University of Medical Sciences, Bushehr, Iran
  2. 2. Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Dr. Mohajeri Laboratory of Isfahan, Isfahan, Iran
  4. 4. Department of Epidemiology, Persian Gulf Tropical Medicine Research Centre, Bushehr University of Medical Sciences, Bushehr, Iran
  5. 5. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  6. 6. Department of Immunology, Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran

Source: APMIS Published:2016


Abstract

Human epidermal growth factor receptor-2 is an important and prognostic factors and one of the most targeted proteins in breast cancer's therapy. There is no globally accepted method for determining its status. Here, we aimed to evaluate the immunohistochemistry method validity in predicting HER-2 status by Fluorescence in situ hybridization method and investigate some clinicopathological variables association with HER-2 amplification. A total of 190 HER-2 2+ and 3+ by immunohistochemistry (IHC) invasive breast cancer cases were enrolled in this study. Fluorescence in situ hybridization (FISH) was performed for these cases using FDA criteria and the association between clinicopathological variables and HER-2 status evaluated. Study consisted of 190 invasive breast cancer patients (160 HER-2 2+ and 30 HER-2 3+). HER-2 FISH amplification according to FDA criteria was found 27.5% (44/160 patients) in HER-2 2+ patients and 83.3% (25/30 patients) in HER-2 3+ patients. Tumors with HER-2 amplification were more likely to be ER-negative (51.0% vs 31.2%, p = 0.013) and PR-negative (52.9% vs 27.0%, p < 0.001). This study showed that immunohistochemistry is not a good method for evaluating HER-2 status and decision-making about trastuzumab therapy even with 3+ score patients. However, this result may not be too strong for IHC 3+ cases due to the limited number of these patients in this study. © 2016 APMIS Published by John Wiley & Sons Ltd.
Related Docs
View other Related Docs
1. Evaluation of Immunohistochemistry Technique in Detecting Her2 Overexpression in Invasive Ductal Breast Carcinoma Using Fluorescence In-Situ Hybridization Method, Journal of Isfahan Medical School (2016)
2. The Correlation of Cd19 + Cd24 + Cd38 + B Cells and Other Clinicopathological Variables With the Proportion of Circulating Tregs in Breast Cancer Patients, Breast Cancer (2017)
3. Discordance of Human Epidermal Growth Factor Receptor-2 Expression in Primary Breast Cancer and Related Axillary Lymph Node Metastasis, Asian Journal of Pharmaceutics (2018)
4. Association of Mammographic and Sonographic Findings With Prognostic Molecular Factors and Hormone Receptor Expression in Malignant Breast Lesions, Journal of Research in Medical Sciences (2024)
5. Multicentricity in Different Molecular Subtypes of Breast Cancer: A Cross-Sectional Study in Isfahan, Advanced Biomedical Research (2023)
6. The Prognostic Significance of Her2-Neu Over Expression in Gastric Carcinomas, Iranian Journal of Cancer Prevention (2011)
7. New Insights Into Affinity Proteins for Her2-Targeted Therapy: Beyond Trastuzumab, Biochimica et Biophysica Acta - Reviews on Cancer (2020)
8. Linear and Conformational B Cell Epitope Prediction of the Her 2 Ecd-Subdomain Iii by in Silico Methods, Asian Pacific Journal of Cancer Prevention (2012)
Experts (# of related papers)
View all Related Experts
Abbas Jafarian (4)
Vajihe Akbari (3)
Other Related Docs
9. Improved Biological Activity of a Single Chain Antibody Fragment Against Human Epidermal Growth Factor Receptor 2 (Her2) Expressed in the Periplasm of Escherichia Coli, Protein Expression and Purification (2015)
10. Association Between Radio-Pathological Breast Tumor Characteristics and Mammographic Breast Density, Archives of Breast Cancer (2024)
11. A Rapid and Sensitive Method for Ephb4 Identification As a Diagnostic and Therapeutic Biomarker in Invasive Breast Cancer, Journal of Cancer Research and Therapeutics (2016)
12. Mir-195 Down-Regulation Is a Distinctive Biomarker of Her2 Positive State in Breast Cancer, Gene Reports (2020)
13. Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial, BMC Cancer (2022)
14. Diagnostic Values of Ultrasound and Mammography on Prediction of Lymphovascular Invasion in Breast Cancer, Indian Journal of Gynecologic Oncology (2025)
15. Design and Construction of Scfv-Pe35kdel As a Novel Immunotoxin Against Human Epidermal Growth Factor Receptor 2 for Cancer Therapy, Biotechnology Letters (2023)
16. In Silico Design of Discontinuous Peptides Representative of B and T-Cell Epitopes From Her2-Ecd As Potential Novel Cancer Peptide Vaccines, Asian Pacific Journal of Cancer Prevention (2013)
17. Comparison of the Structural, Cytological and Biomarker Expression in Carcinoma in Situ and Invasive Components in Breast Carcinoma, Iranian Journal of Pathology (2024)
18. Expression of Basal and Luminal Cytokeratins in Breast Cancer and Their Correlation With Clinicopathological Prognostic Variables, Indian Journal of Medical Sciences (2009)
19. Investigation of Her-2 Expression and Its Correlation With Clinicopathological Parameters and Overall Survival of Esophageal Squamous Cell Carcinoma Patients, Iranian Journal of Pathology (2020)
20. Investigation of Prognostic Factors in Breast Cancer and Their Relationship With Age and Cancer Stage, Journal of Isfahan Medical School (2012)
21. Association of the Length of Ca Dinucleotide Repeat in the Epidermal Growth Factor Receptor With Risk and Age of Breast Cancer Onset in Isfahan, Journal of Isfahan Medical School (2008)
22. Production and Characterization of New Anti-Her2 Monoclonal Antibodies, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2015)
23. Comparison of Breast Tumor Size Measurement Using Ultrasound and Mammography With Pathologic Report Following Mastectomy or Lumpectomy, Journal of Isfahan Medical School (2022)